“…Although corticosteroids are established immunosuppressive agents, their action is not selective and they cause metabolic and endocrinal side effects [9], whereas compounds with IL-5 inhibitory activity act selectively in reducing eosinophilic inflammation. In the literature small molecules are referred as IL-5 inhibitors (Figure 1): chalcones [10,11], isothiazolones through modification of Cys66 (Cysteine66) in IL-5Ra (interleukin 5 receptor subunit alpha) [12], isoflavonones as sophoricoside analogues [13,14], hydroxyalkylaminomethylchromones [15], derivatives based on hydroxyethylaminomethyl-4H-chromen-4-one scaffold [16], chromone analogues [17], isoflavones and aurones [18]. Mepolizumab and reslizumab, two monoclonal anti-IL-5 antibodies, and benralizumab, a monoclonal antibody directed at the IL-5 receptor, have been tested in clinical trials for the treatment of bronchial asthma, nasal polyposis, atopic dermatitis, eosinophilic oesophagitis, hypereosinophilic syndrome and Churg-Strauss syndrome [19].…”